Genotype variant associated with add-on memantine in bipolar II disorder

scientific article published on 9 October 2013

Genotype variant associated with add-on memantine in bipolar II disorder is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1017/S1461145713000825
P698PubMed publication ID24103632

P50authorJau-Shyong HongQ63384716
P2093author name stringRu-Band Lu
I Hui Lee
San-Yuan Huang
Sheng-Yu Lee
Shih-Heng Chen
Shiou-Lan Chen
Tzung Lieh Yeh
Yen Kuang Yang
Yun-Hsuan Chang
Nian-Sheng Tzeng
Liang-Jen Wang
Chen-Lin Wang
Chun-Hsieh Chu
P2860cites workPsychosocial Disability in the Course of Bipolar I and II DisordersQ22253033
A rating scale for depressionQ24564540
Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behaviorQ24679793
The bipolar spectrumQ28290726
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal functionQ29615582
Development of a Rating Scale for Primary Depressive IllnessQ29616244
A rating scale for mania: reliability, validity and sensitivityQ29619299
Neuroimaging in bipolar disorder: what have we learned?Q30615539
The evolving bipolar spectrum. Prototypes I, II, III, and IV.Q33768203
Neuroimaging studies of mood disordersQ33924331
Exercise: a behavioral intervention to enhance brain health and plasticityQ33959877
Pharmacogenetics of psychotropic drug responseQ33977981
Models for longitudinal data: a generalized estimating equation approachQ34170659
A diagnostic interview: the schedule for affective disorders and schizophreniaQ34269355
Effects of BDNF polymorphisms on antidepressant action.Q34497530
The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trialQ34633307
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorderQ34871885
Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effectsQ35016570
Low-dose memantine attenuated morphine addictive behavior through its anti-inflammation and neurotrophic effects in ratsQ36725510
Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation.Q36848206
Bipolar II disorder: arguments for and against a distinct diagnostic entityQ37058584
Ethnic differences in brain-derived neurotrophic factor Val66Met polymorphism in Croatian and Korean healthy participantsQ37133128
The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study.Q37219127
Pharmacogenomics of antidepressant drugsQ37535096
Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysisQ37873034
The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidenceQ38025454
Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episodeQ39270744
Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patientsQ40318595
Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brainQ40771649
Differentiation of Primary Affective Illness From Situational, Symptomatic, and Secondary DepressionsQ41604416
Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorderQ43011122
How can we realize the promise of personalized antidepressant medicines?Q44045526
Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependenceQ44845104
Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice.Q45068824
Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorderQ45079329
Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation.Q45924452
Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodentsQ46612624
Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorderQ46694309
Association of the brain-derived neurotrophic factor gene and bipolar disorder with early age of onset in mainland ChinaQ46776793
Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine.Q46922833
Association of BDNF gene polymorphism with bipolar disorders in Han Chinese population.Q47825016
Ethnic difference of the BDNF 196G/A (val66met) polymorphism frequencies: the possibility to explain ethnic mental traitsQ47867995
Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophreniaQ48186144
Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidanceQ48315286
Novel therapeutic approaches beyond the serotonin receptorQ48385350
Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disordersQ48401011
Association study of the brain-derived neurotrophic factor (BDNF) gene with bipolar disorderQ48411017
Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosisQ48582986
Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodesQ48649203
Subgenual prefrontal cortex abnormalities in mood disordersQ48725544
The NMDA antagonist memantine blocks the expression and maintenance of morphine dependenceQ49021766
Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania.Q51032825
The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders?Q51951357
Differential features between bipolar I and bipolar II disorderQ57612992
Cyclothymic disorder: validating criteria for inclusion in the bipolar affective groupQ67690092
Bipolar II depression in late life: prevalence and clinical features in 525 depressed outpatientsQ74452760
The emerging epidemiology of hypomania and bipolar II disorderQ77700788
Recurrence of bipolar disorders and major depression. A life-long perspectiveQ79077975
Changes in insight among patients with bipolar I disorder: a 2-year prospective studyQ80149571
P433issue2
P304page(s)189-197
P577publication date2013-10-09
P1433published inThe International Journal of NeuropsychopharmacologyQ7742309
P1476titleGenotype variant associated with add-on memantine in bipolar II disorder
P478volume17

Reverse relations

cites work (P2860)
Q39145461A Meta-Analysis of Memantine for Depression.
Q48064476A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate
Q33721019Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders
Q28066714The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm

Search more.